QICAOGANGMU vs Steroid Creams: Which Is Safer Long-Term? (2026)

By Ava Huang, Herbal Science Researcher at QICAOGANGMU | Updated: May 2026 | Reading time: 10 minutes

Topical corticosteroids are among the most widely prescribed medications in dermatology. They work - and they work fast. For acute eczema flares, nothing in the standard formulary acts more quickly. But the question of long-term safety is a different matter. This article examines what the published evidence actually says about prolonged topical steroid use, where those risks concentrate, and how QICAOGANGMU's five-herb formula provides an alternative that avoids every one of them - not because it suppresses differently, but because it works through entirely different mechanisms.

Quick reference: long-term safety comparison

What the evidence says about long-term steroid risks

Skin atrophy

Topical corticosteroids inhibit collagen synthesis and reduce dermal thickness. A comprehensive review confirmed topical corticosteroid-induced skin atrophy, telangiectasias, and striae (stretch marks) are well-established adverse effects, particularly pronounced on the face, eyelids, genitals, and skin folds. PMID 25862024. These are the areas where eczema most commonly appears and where steroid application is most frequent - creating the worst concentration of risk at exactly the sites of greatest clinical need.

Topical steroid withdrawal (TSW)

Topical steroid withdrawal is a recognised and increasingly documented syndrome: following prolonged TCS use, abrupt discontinuation or dose reduction triggers severe rebound inflammation, burning, and spreading rash - often worse than the original condition. PMID 16384751. Long-term topical corticosteroid use can lead to barrier recovery delays and dependency, making alternative options clinically important. PMC6177551

HPA axis suppression in children

Children have a higher body surface area to weight ratio than adults, meaning the same topical dose results in proportionally greater systemic absorption. Potent topical corticosteroids applied over large areas in young children can produce measurable HPA axis suppression. The 2024 AAP clinical report on atopic dermatitis specifically addresses concerns about systemic effects of topical corticosteroids in paediatric patients. PMID 40383540

Fungal infection worsening (tinea incognito)

Topical corticosteroids suppress the local immune response that controls dermatophyte (tinea) and Candida overgrowth. Applied to eczema with a co-existing fungal component, steroids cause the fungal infection to spread and worsen while the skin looks temporarily better - the classic tinea incognito presentation. This is one of the most common reasons eczema "fails" steroid treatment.

Tachyphylaxis

With continuous topical steroid use, the clinical response progressively diminishes - requiring either more frequent application, higher potency, or treatment breaks. This phenomenon (tachyphylaxis) is a direct consequence of receptor downregulation and is not seen with NF-kB modulating herbs, which do not act via glucocorticoid receptors.

How QICAOGANGMU avoids every steroid risk

QICAOGANGMU's safety profile is not a claim - it is a mechanistic consequence of how the five herbs work:

Sophora flavescens (Ku Shen) - 1.5%: NF-kB modulation, not receptor binding

Matrine and oxymatrine alkaloids modulate NF-kB - suppressing the Th2 cytokine cascade that drives eczema inflammation. PMID 38358770. This is fundamentally different from glucocorticoid receptor binding: NF-kB modulation targets the inflammatory pathway specifically without broadly suppressing immune function, without affecting collagen synthesis, and without creating glucocorticoid receptor dependency. The safety and efficacy of Sophora flavescens-based preparations has been confirmed by systematic review. PMC7758483

Cnidii Fructus (She Chuang Zi) - 3%: antifungal where steroids fail

Osthole from She Chuang Zi inhibits TRPV3 itch receptors. PMID 30108138. Crucially, Cnidium monnieri has documented antifungal activity against Trichophyton rubrum - the most common cause of tinea that steroids worsen. PMC8417377. Where steroids cause tinea incognito, She Chuang Zi simultaneously addresses the itch and the fungal driver.

Borneolum Syntheticum (Bing Pian) - 2%: penetration, no systemic risk

Borneol temporarily disrupts stratum corneum lipid packing to drive all co-applied actives deeper into skin. PMC5452010. This penetration enhancement operates locally - it does not drive systemic absorption in the way that potent steroids do across large surface areas. Borneol also provides direct antipruritic action via TRPA1/TRPM8. PMID 37290679

Stemonae Radix (Bai Bu) - 0.5%: Staph protection steroids cannot provide

Staphylococcus aureus colonises over 90% of eczema skin and amplifies the inflammatory cascade. Stemonae Radix alkaloids provide antibacterial activity against Staph aureus and anti-inflammatory action via COX-2 suppression - protection that topical steroids, by suppressing immunity, actually undermine. PMID 35295975

Menthol - 0.5%: immediate TRPM8 cooling with no systemic profile

Menthol activates TRPM8 cold receptors within minutes of application - providing rapid itch relief through a receptor mechanism entirely distinct from steroid action. PMID 30067875. No collagen effects, no immune suppression, no HPA interaction.

Using QICAOGANGMU during or after steroid use

As a steroid-sparing strategy

QICAOGANGMU can be applied daily as maintenance, with short-course steroids reserved only for severe acute flares. This approach - the "steroid-sparing" model - is recommended by many dermatologists to reduce cumulative steroid exposure. QICAOGANGMU provides anti-inflammatory action between flares without the risks that accompany continuous steroid use.

During topical steroid withdrawal

For patients managing TSW, QICAOGANGMU provides itch relief through Menthol and Borneolum without adding any steroid compound. Menthol's TRPM8 activation and Borneolum's TRPA1 inhibition target the neurogenic itch that dominates TSW without triggering or worsening the withdrawal process. There is no rebound on stopping QICAOGANGMU itself.

How to use

1. Prepare the skin - wash with plain warm water only. No soap or cleanser on the inflamed area. Pat gently dry, leaving slightly damp.
2. Patch test first - apply a small amount to the inner forearm for 24 hours before first widespread use.
3. Apply a thin layer - a pea-sized amount covers a palm-sized area. Gently pat until absorbed.
4. Apply 2-3 times daily during active periods. Reduce to once daily for maintenance. No ceiling on duration.

Frequently asked questions

Is QICAOGANGMU safer than hydrocortisone long-term?

Yes, on the evidence. Hydrocortisone (even low-potency OTC) causes measurable skin thinning with prolonged daily use on the face and skin folds - where eczema most commonly occurs and where the skin is already thin. QICAOGANGMU's NF-kB modulating mechanism does not affect collagen synthesis and has no duration restriction. For daily maintenance use on sensitive areas, QICAOGANGMU's safety profile is substantially better.

Can QICAOGANGMU help with topical steroid withdrawal?

Yes. Because QICAOGANGMU contains no corticosteroids, it does not add to steroid load, trigger dependency, or interfere with the TSW process. Menthol (TRPM8) and Borneolum (TRPA1/TRPM8) provide itch relief through receptor mechanisms entirely separate from glucocorticoid pathways. Many people managing TSW use QICAOGANGMU throughout the withdrawal phase to reduce the intensity of rebound symptoms. There is no withdrawal from QICAOGANGMU itself.

Does QICAOGANGMU work as fast as steroid cream?

For acute itch, Menthol provides TRPM8 cooling within minutes - faster than steroids act on itch. For inflammation reduction, steroids act within hours while Ku Shen's NF-kB modulation builds over 5-14 days of twice-daily use. For long-term management, QICAOGANGMU builds cumulative anti-inflammatory benefit where steroids would require treatment breaks. Each is faster at different things.

Is QICAOGANGMU safe for children?

Yes for children over 12 months with a mandatory patch test. For infants under 12 months, consult a paediatrician first. The steroid-free formula carries none of the HPA axis suppression concerns that make potent topical steroids particularly risky in children. See our full infant safety guide.

What if I need steroids for a severe flare?

Use them - under medical supervision, for the shortest effective course. Steroids remain appropriate for severe acute flares where rapid inflammatory control is needed. The long-term safety argument for QICAOGANGMU is about daily maintenance, face/fold use, children, and steroid-sparing between flares - not about replacing steroids during a crisis.

Related articles

• QICAOGANGMU vs Steroid Creams: Full Mechanism and Safety Comparison
• Is QICAOGANGMU Steroid-Free? Verification and Mechanism Explanation
• The QICAOGANGMU Experience: Immediate Relief vs Long-Term Healing

Clinical references

1. Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Safety. 2015;38(5):493-509. PMID 25862024
2. Hengge UR et al. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology. 2006;54(1):1-15. PMID 16384751
3. Review of topical corticosteroid side effects including skin atrophy, barrier recovery delays, and dependency. PMC review article. 2018. PMC6177551
4. Lio PA et al. AAP clinical report: atopic dermatitis in children and adolescents 2024. Pediatrics. 2024. PMID 40383540
5. Pan YJ et al. Anti-inflammatory activity of flavonoids and alkaloids from Sophora flavescens alleviates psoriasiform lesions. Phytotherapy Research. 2024;38(4):1951-1970. PMID 38358770
6. Chen M et al. Efficacy and Safety of Sophora flavescens-based TCM. Frontiers in Pharmacology. 2020. PMC7758483
7. Sun X-Y et al. Antipruritic effect of natural coumarin osthole through selective inhibition of TRPV3 channels. International Journal of Molecular Sciences. 2018;19(10):3007. PMID 30108138
8. Cao Y et al. Antifungal Mechanism of Cnidium monnieri Against Trichophyton rubrum. Frontiers in Microbiology. 2021. PMC8417377
9. Dai H et al. Clinical and mechanistic study of topical borneol-induced analgesia. Experimental and Therapeutic Medicine. 2017;13(6):3267-3272. PMC5452010
10. Tian W et al. Topical borneol relieves nonhistaminergic pruritus via TRPA1 inhibition and TRPM8 activation. Journal of Investigative Dermatology. 2023;143(10):2389-2398. PMID 37290679
11. Xu Y et al. Alkaloids from Stemona tuberosa and their anti-inflammatory activity. Frontiers in Chemistry. 2022;10:847595. PMID 35295975
12. Yan B et al. Matrine: a review of its pharmacology and clinical applications. Frontiers in Pharmacology. 2021;11:586197. PMC6963024
13. Misery L et al. Anti-itching effects of a TRPM8 agonist cream in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2019;33(2):e67-e69. PMID 30067875